These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 39421166)

  • 1. The use of immune checkpoint inhibitors in advanced gastric/gastroesophageal adenocarcinomas - real-world evidence and the use of alternative dosing.
    Dhanawat A; Trikha M; Vora M; Gujarathi H; Ostwal V; Bhargava P; Kaushal R; Ramaswamy A
    Ecancermedicalscience; 2024; 18():1741. PubMed ID: 39421166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of Low-Dose Immunotherapy and Standard-Dose Immunotherapy in Microsatellite Instability-High Metastatic Colorectal Cancer: Real-World Data (CLouD-High Study).
    Trikha M; Sarkar L; Dhanawat A; Syed N; Gujarathi H; Vora M; Sivakumar Raja AS; Bhargava P; Ramaswamy A; Mandavkar S; Saklani A; Kaushal RK; Bal M; Shetty O; Yadav S; Ostwal V
    JCO Glob Oncol; 2024 Aug; 10():e2400141. PubMed ID: 39159410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
    Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ
    JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.
    Kundel Y; Sternschuss M; Moore A; Perl G; Brenner B; Goldvaser H
    Cancer Med; 2020 Oct; 9(20):7613-7625. PubMed ID: 32869544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.
    Fei S; Lu Y; Chen J; Qi J; Wu W; Wang B; Han Y; Wang K; Han X; Zhou H; Wang J; Chen J
    Chemotherapy; 2023; 68(4):197-209. PubMed ID: 37331333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.
    Schlintl V; Huemer F; Rinnerthaler G; Melchardt T; Winder T; Reimann P; Riedl J; Amann A; Eisterer W; Romeder F; Piringer G; Ilhan-Mutlu A; Wöll E; Greil R; Weiss L
    BMC Cancer; 2022 Jan; 22(1):51. PubMed ID: 35012477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials.
    Dubois M; Liscia N; Brunetti O; Ziranu P; Lai E; Argentiero A; Mazza E; Cascinu S; Silvestris N; Casadei-Gardini A; Scartozzi M
    Crit Rev Oncol Hematol; 2022 May; 173():103674. PubMed ID: 35364261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort.
    Taïeb J; Sayah L; Heinrich K; Kunzmann V; Boileve A; Cirkel G; Lonardi S; Chibaudel B; Turpin A; Beller T; Hautefeuille V; Vivaldi C; Mazard T; Bauguion L; Niger M; Prager GW; Coutzac C; Benedikt Westphalen C; Auclin E; Pilla L
    Eur J Cancer; 2023 Jul; 188():90-97. PubMed ID: 37229836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
    Shitara K; Van Cutsem E; Bang YJ; Fuchs C; Wyrwicz L; Lee KW; Kudaba I; Garrido M; Chung HC; Lee J; Castro HR; Mansoor W; Braghiroli MI; Karaseva N; Caglevic C; Villanueva L; Goekkurt E; Satake H; Enzinger P; Alsina M; Benson A; Chao J; Ko AH; Wainberg ZA; Kher U; Shah S; Kang SP; Tabernero J
    JAMA Oncol; 2020 Oct; 6(10):1571-1580. PubMed ID: 32880601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer.
    Kim H; Kim H; Lee M; Kwon M; Hong JY; Lee J; Lim HY; Kang WK; Kim ST
    J Cancer; 2021; 12(18):5681-5686. PubMed ID: 34405028
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment and Survival in Advanced Non-Small Cell Lung Cancer, Urothelial, Ovarian, Gastric and Kidney Cancer: A Nationwide Comprehensive Evaluation.
    Sørup S; Darvalics B; Khalil AA; Nordsmark M; Hæe M; Donskov F; Agerbæk M; Russo L; Oksen D; Boutmy E; Verpillat P; Cronin-Fenton D
    Clin Epidemiol; 2021; 13():871-882. PubMed ID: 34588817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.
    Fuchs CS; Özgüroğlu M; Bang YJ; Di Bartolomeo M; Mandala M; Ryu MH; Fornaro L; Olesinski T; Caglevic C; Chung HC; Muro K; Van Cutsem E; Elme A; Thuss-Patience P; Chau I; Ohtsu A; Bhagia P; Wang A; Shih CS; Shitara K
    Gastric Cancer; 2022 Jan; 25(1):197-206. PubMed ID: 34468869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10.
    Wainberg ZA; Fuchs CS; Tabernero J; Shitara K; Muro K; Van Cutsem E; Bang YJ; Chung HC; Yamaguchi K; Varga E; Chen JS; Hochhauser D; Thuss-Patience P; Al-Batran SE; Garrido M; Kher U; Shih CS; Shah S; Bhagia P; Chao J
    Clin Cancer Res; 2021 Apr; 27(7):1923-1931. PubMed ID: 33446564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of Trial-Like and Non-Trial-Like Patients With Immunotherapy in Advanced Hepatocellular Carcinoma in Real World: A Collaborative Multicenter Indian Study (IMHEP).
    Ramaswamy A; Kulkarni A; John G; Rauthan A; Patil S; Duseja A; Talwar V; Rajappa SJ; Ghadyalpatil N; Wadhawan M; Shukla A; Krishna VM; Srinivas S; Taneja S; Sravani KM; Rathi S; Bhargava P; Ostwal V
    JCO Glob Oncol; 2023 Sep; 9():e2300215. PubMed ID: 38033275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitors.
    Ghelardi F; Fucà G; Cavalli C; Shitara K; Cohen R; Ambrosini M; Maron SB; Cerantola R; Nasca V; Liberti GD; Zambelli L; Palazzo M; Salati M; Aoki Y; Kawazoe A; Cowzer D; Lonardi S; André T; Randon G; Pietrantonio F
    Dig Liver Dis; 2024 May; ():. PubMed ID: 38772790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the efficacy and safety of first- and second-line immunotherapy in patients with metastatic colorectal cancer: a systematic review and network meta-analysis based on randomized controlled trials.
    Chen K; Chen W; Yue R; Zhu D; Cui S; Zhang X; Jin Z; Xiao T
    Front Immunol; 2024; 15():1439624. PubMed ID: 39359729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
    Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer.
    Ambrosini M; Tougeron D; Modest D; Guimbaud R; Kopetz S; Decraecker M; Kim S; Coutzac C; Perkins G; Alouani E; Marmorino F; Pernot S; Sinicrope FA; Elez E; Parent P; Cremolini C; Pietrantonio F; Lonardi S; Gallois C; Taieb J
    Eur J Cancer; 2024 Oct; 210():114290. PubMed ID: 39216175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors combined with paclitaxel-based chemotherapy versus chemotherapy alone as first-line treatment in HER2-negative advanced gastric cancer: result of a multicenter retrospective study.
    Fang Y; Zhao Y; Yu X; Liu S; Tao G; Zhong H; Xiang H; Yang Y; Shi Z
    J Gastrointest Oncol; 2024 Apr; 15(2):585-596. PubMed ID: 38756641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.